Chelsea halves workforce to focus on Northera approval trial
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics founder, president and CEO Simon Pedder has resigned and the company said on 10 July that it will cut its workforce nearly in half to reduce expenses and focus its resources on a single goal: US FDA approval for Northera (doxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (neurogenic OH).